Individuals with cutaneous lupus erythematosus have an increased ASCVD risk when compared with those without cutaneous lupus erythematosus.

Systemic lupus erythematosus, more commonly known as lupus, has a variety of symptoms and room for improvement when it comes ...

Interferon-alpha activity may be used routinely in clinical settings as a biomarker for cutaneous lupus erythematosus and ...

Systemic lupus erythematosus commonly presents as a rash. The rashes are caused by inflammation from the immune system fighting the body. Systemic lupus erythematosus, more commonly known as lupus ...

Adicet Bio, Inc. (ACET), a clinical stage biotechnology company, Wednesday said it received Fast Track Designation from the U.S. Food ...

In a new study published in Lupus Science & Medicine, researchers assessed clinical trial perceptions among a predominantly Black cohort of participants with systemic lupus erythematosus (SLE).

Systemic lupus erythematosus (SLE) can have links with sleep disorders such as insomnia and obstructive sleep apnea. Lupus can also make you wake up more in the night. If lupus is affecting the ...

Cutaneous lupus erythematosus (CLE) is associated with an increased risk for atherosclerotic cardiovascular disease (ASCVD).

EULAR/ACR SLE classification criteria were not linked to mortality or hospitalization, a developed ominosity model adequately predicted mortality.

found that 27% of individuals with systemic lupus erythematosus (SLE) had hearing loss. This was significantly higher than in the control group. Participants with SLE showed worse hearing at lower ...

Systemic lupus erythematosus (SLE) often presents with neuropsychiatric (NP) involvement, including cognitive impairment and depression. Past magnetic resonance imaging (MRI) research in SLE patients ...

Roche’s subsidiary Genentech has shared positive Phase III data with the US Food and Drug Administration (FDA) as the company targets the billion-dollar lupus market for its CD20-targeting drug Gazyva ...